Figure 2From: Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer Kaplan-Meier survival analyses of the 394 breast cancer patients. Disease-free survival (A) and overall survival (B) of the 394 breast cancer patients stratified according to the presence or absence of NAT1 protein.Back to article page